Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Indivior Pharmaceuticals, Inc. - Common Stock (NQ:INDV)

36.40 +1.03 (+2.91%)
Delayed Quote Updated: 10:07 AM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Indivior Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Indivior Reports Third Quarter 2026 Financial Results
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior to Report Third Quarter 2026 Financial Results
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether ITGR, FHB, INDV, LNTH are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
Payment of Special Dividend Contingent upon Closing of the Pending Merger Transaction 
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether INDV, FHB, BGMS are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Halper Sadeh LLC is Investigating Whether LNTH, ATKR, INDV are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
From Supernus Pharmaceuticals, Inc.; Indivior Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Indivior to Report Second Quarter 2026 Financial Results and Host Webcast
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior to Participate in Upcoming Investor Conferences
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior Announces $175 Million Accelerated Share Repurchase
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior Announces Proposed Convertible Senior Notes Offering
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior to Participate in Upcoming Investor Conferences
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior Announces Completion of Redomiciliation to the United States
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior Provides Full-Year 2026 Financial Guidance and Business Update
From Indivior Inc.
Via GlobeNewswire
News headline image
INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Indivior PLC (INDV)
From The Law Offices of Frank R. Cruz
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.